@IamEmchee profile picture
Emerson Chen @IamEmchee

GI oncologist and health services researcher at Oregon Health & Science University

Joined December 2014
  • Tweets 23
  • Following 98
  • Followers 120
Photos and videos
Emerson Chen retweeted
Axel Grothey@agrothey
11 Sep 2020
Pembro in “TMB high” (10 ) cancers - paper published in Lancet Oncol. No difference in OS between TMB high and TMB low. Neverthelessless FDA approved. SMH. @OncoAlert
10
76
210
Emerson Chen retweeted
Bernie Marini@Berninini
30 May 2020
Friendly reminder that surrogate endpoints like PFS only reduce study time by an average of 11 months - @IamEmchee, et al. 🙂 We shouldn’t proclaim new therapies as “new standard of care”, without showing OS or QOL benefit for patients. #ASCO2020 #asco20 jamanetwork.com/journals/jam…

Study Time Estimates Using Surrogate End Points vs Overall Survival in Oncology Clinical Trials

This study analyzes the original and updated clinical trials that led to FDA-approved drug indications in oncology from 2006 to 2017 to assess reduction in clinical trial duration derived from using...

jamanetwork.com
8
25
Critical Care and the COVID-19 Outbreak in Italy: Early Experience and Forecast ja.ma/2wTgyUH
Emerson Chen retweeted
Ryan Huey, MD, MS@ryanhuey
25 Jan 2020
Dr. Christopher Booth reminds us about endpoints that matter to patients. #GI20
3
34
107
Canada's Transparency With Clinical Trial Puts Pressure On U.S. FDA To Reveal More : Shots - Health News : NPR npr.org/sections/health-shot…

Canada's Decision To Make Public More Clinical Trial Data Puts Pressure On FDA

The U.S. Food and Drug Administration treats most data it gets on the development of new drugs and medical devices as confidential to companies. Critics say making the data public would help patients.

npr.org
1
Couldn’t agree more, would like to tell my patients how a new therapy will directly help them. “Surrogate End Points and Patient-Reported Outcomes for Novel Oncology Drugs” ja.ma/2nolHiy
1
Wow amazing online course that changed how I think about oncology drugs, and completed just in time before my first day as faculty tomorrow @edxonline #mooc edx.org/course/the-fda-and-p…
2
Emerson Chen retweeted
Elizabeth Warren
@SenWarren
2 Jul 2019
I look forward to a response and hope Dr. @ScottGottliebMD will rectify his mistake & resign from his position at @Pfizer. It would send a strong message about the importance of integrity of current & former federal officials.
85
195
1,017
Health policy conundrum, 1) gets cancer drug approved faster but more uncertainty 2) might not get drug approved but more certainty of clinical benefit jamanetwork.com/journals/jam…

Study Time Estimates Using Surrogate End Points vs Overall Survival in Oncology Clinical Trials

This study analyzes the original and updated clinical trials that led to FDA-approved drug indications in oncology from 2006 to 2017 to assess reduction in clinical trial duration derived from using...

jamanetwork.com
Shaalan Beg MD MBA FASCO@ShaalanBeg
24 Jun 2019
Replying to @GIcancerDoc @pashtoonkasi @aakonc @UqbaKhan @kmody29 @DrR_DUNNE @gabe_a_brooks @agrothey @utswcancer @ASCOPost
great point.. raises the question, should one design a trial aimed at the 1) end point you can achieve or 2) the end point which is more meaningful?
1
2
I find the sicker treatment-refractory patient tend to be on left and the healthier adjuvant/first-line metastatic patient on the right.
Michael Fisch MD MPH@fischmd
4 Jun 2019
Replying to @barttels2 @oncology_bg @ASCO @ecancer @scottrberry @cpgYALE @yzafar @MartinStockler @Prof_IanD @NicoleKuderer @JackWestMD
The bargain of accelerated approvals and the spectrum of patient viewpoints on this issue was described brilliantly by @VPrasadMDMPH at #ASCO19
2
Emerson Chen retweeted
Yousuf Zafar, MD MHS@yzafar
3 Jun 2019
Len Saltz @sloan_kettering listing no-value interventions in #colorectalcancer Anything to add or subtract? #ASCO19 #crcsm
6
18
33
Emerson Chen retweeted
Tatiana Prowell, MD@tmprowell
4 Jun 2019
On interpreting #clinicaltrials: When you hear “A HR of __ & a __month diff in PFS,” consider what the control arm is. The interpretation of those #s differs if comparator is placebo/BSC or active control, & if active control, if new drug is an add on or replacement tx. #ASCO19
1
12
36
Emerson Chen retweeted
Sam Sater, MD@HSaterMD
2 Jun 2019
ANNOUNCE failed to meet OS primary endpoint and Olaratumab will be withdrawn after previous initial FDA @US_FDA approval. #ASCO19 #ASCO2019 #sarcoma #pdgfra
17
21
Emerson Chen retweeted
Bishal Gyawali, MD, PhD, FASCO
@oncology_bg
2 Jun 2019
In light of today’s #ASCO19 plenary, please read our latest @JAMAInternalMed paper on accelerated approval to understand this pathway’s trade offs. We even managed to sneak in a sentence about #olaratumab at the very last moment. jamanetwork.com/journals/jam… #ASCOplenary #sarcoma
4
6
Emerson Chen retweeted
Michael Fisch MD MPH@fischmd
31 May 2019
“Clinical trials are there to serve patients, not the other way around.” —@oncology_bg #ASCO19 #bcsm #lcsm #crcsm #mmsm
4
33
78
Emerson Chen retweeted
Bishal Gyawali, MD, PhD, FASCO
@oncology_bg
28 May 2019
And here’s the story covered by @rrichardh in the NPR : npr.org/sections/health-shot…

1
1
8
Emerson Chen retweeted
Bishal Gyawali, MD, PhD, FASCO
@oncology_bg
28 May 2019
The biggest honor, however, is to have 2 editorials accompany our paper. I always lamented @RichardLehman1 ‘s retiring from BMJ blogs without getting chance to read his comment on my work. But now he has written an editorial instead with @cpgYALE . jamanetwork.com/journals/jam… 🙏

2
5
14
Emerson Chen retweeted
Bishal Gyawali, MD, PhD, FASCO
@oncology_bg
28 May 2019
Another brilliant editorial is from Zeke Emmanuel et al. You’ll enjoy every word of this. jamanetwork.com/journals/jam…

1
4
8
Emerson Chen retweeted
Bishal Gyawali, MD, PhD, FASCO
@oncology_bg
28 May 2019
Published just now in @JAMAInternalMed . Our assessment of the Clinical Benefit of Cancer Drugs Receiving Accelerated Approval. jamanetwork.com/journals/jam… @SpencerPHey @akesselheim @PORTAL_Research @BrighamResearch @QueensUHealth
5
37
68
Aspired to be a plain “trialist” but ended up looking at 170 cancer drug registration trials since 2006: “Study Time Estimates Using Surrogate End Points vs Overall Survival in Oncology Clinical Trials” ja.ma/2K3bP8L

2
5
21
Load more